Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer.

Gentile D, Orlandi P, Banchi M, Bocci G.

Med Oncol. 2020 Feb 27;37(3):19. doi: 10.1007/s12032-020-1345-2. Review.

PMID:
32108281
2.

Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer.

Fornaro L, Vivaldi C, Orlandi P, Musettini G, Pecora I, Gentile D, Catanese S, Lencioni M, Salani F, Pasquini G, Massa V, Di Desidero T, Falcone A, Vasile E, Bocci G.

Ann Oncol. 2019 Jul;30 Suppl 4:iv88. doi: 10.1093/annonc/mdz155.318. Epub 2019 Dec 4. No abstract available.

PMID:
32085331
3.

How many rare diseases are there?

Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, Hamosh A, Baynam G, Groza T, McMurry J, Dawkins H, Rath A, Thaxon C, Bocci G, Joachimiak MP, Köhler S, Robinson PN, Mungall C, Oprea TI.

Nat Rev Drug Discov. 2020 Feb;19(2):77-78. doi: 10.1038/d41573-019-00180-y. No abstract available.

PMID:
32020066
4.

How to Illuminate the Druggable Genome Using Pharos.

Sheils T, Mathias SL, Siramshetty VB, Bocci G, Bologa CG, Yang JJ, Waller A, Southall N, Nguyen DT, Oprea TI.

Curr Protoc Bioinformatics. 2020 Mar;69(1):e92. doi: 10.1002/cpbi.92.

PMID:
31898878
5.

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells.

Di Desidero T, Orlandi P, Gentile D, Bocci G.

Front Oncol. 2019 Nov 12;9:1202. doi: 10.3389/fonc.2019.01202. eCollection 2019.

6.

Can BDDCS illuminate targets in drug design?

Bocci G, Benet LZ, Oprea TI.

Drug Discov Today. 2019 Dec;24(12):2299-2306. doi: 10.1016/j.drudis.2019.09.021. Epub 2019 Oct 1. Review.

PMID:
31585170
7.

Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter.

Molinaro A, Orlandi P, Niccolai F, Agretti P, De Marco G, Ferrarini E, Di Cosmo C, Vitti P, Piaggi P, Di Desidero T, Bocci G, Tonacchera M.

J Endocrinol Invest. 2020 Feb;43(2):149-155. doi: 10.1007/s40618-019-01092-9. Epub 2019 Aug 2.

PMID:
31376092
8.

Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation.

Quattrini L, Coviello V, Sartini S, Di Desidero T, Orlandi P, Ke YY, Liu KL, Hsieh HP, Bocci G, La Motta C.

Sci Rep. 2019 Jul 9;9(1):9943. doi: 10.1038/s41598-019-46287-5.

9.

Generous breastfeeding: an observational retrospective study of milk donor's characteristics in the province of Siena, Italy.

Bocci G, Kundisova L, Pacini V, Nante N, Alaimo L.

Ann Ig. 2019 Jul-Aug;31(4):316-325. doi: 10.7416/ai.2019.2293.

10.

Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time.

Sarli V, Ciofi L, Lastella M, Muscatello B, Pisaturo F, Paolilli O, Luci G, Cucchiara F, Pellegrini G, Bocci G, Danesi R, Di Paolo A.

Clin Chem Lab Med. 2019 Nov 26;57(12):e331-e333. doi: 10.1515/cclm-2019-0429. No abstract available.

PMID:
31188753
11.

Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.

Orlandi P, Gentile D, Banchi M, Cucchiara F, Di Desidero T, Cremolini C, Moretto R, Falcone A, Bocci G.

Invest New Drugs. 2020 Feb;38(1):92-98. doi: 10.1007/s10637-019-00804-5. Epub 2019 Jun 1.

PMID:
31154566
12.

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

Cox MC, Pelliccia S, Marcheselli L, Battistini R, Arcari A, Borza PA, Patti C, Casaroli I, di Landro F, Di Napoli A, Fabbri F, Caridi M, Tafuri A, Bocci G, Musuraca G.

Invest New Drugs. 2019 Jun;37(3):548-558. doi: 10.1007/s10637-019-00769-5. Epub 2019 Apr 26.

PMID:
31028663
13.

Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.

Di Desidero T, Orlandi P, Fioravanti A, Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F, Antoniotti C, Masi G, Fontanini G, Falcone A, Bocci G.

Biochem Pharmacol. 2019 Jun;164:94-105. doi: 10.1016/j.bcp.2019.04.001. Epub 2019 Apr 3.

PMID:
30953637
14.

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.

Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, Torri V.

Adv Ther. 2019 Feb;36(2):381-406. doi: 10.1007/s12325-018-0844-4. Epub 2018 Dec 18.

PMID:
30565179
15.

Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation.

Manciu M, Hosseini S, Di Desidero T, Allegrini G, Falcone A, Bocci G, Kirken RA, Francia G.

Future Sci OA. 2018 Nov 1;4(10):FSO346. doi: 10.4155/fsoa-2018-0020. eCollection 2018 Dec.

16.

Local and landscape factors affect sunflower pollination in a Mediterranean agroecosystem.

M Bartual A, Bocci G, Marini S, Moonen AC.

PLoS One. 2018 Sep 27;13(9):e0203990. doi: 10.1371/journal.pone.0203990. eCollection 2018.

17.

Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data.

Natale G, Bocci G.

Cancer Lett. 2018 Sep 28;432:28-37. doi: 10.1016/j.canlet.2018.06.002. Epub 2018 Jun 6. Review.

PMID:
29885517
18.

Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.

Pasqualetti F, Pace A, Gonnelli A, Villani V, Cantarella M, Delishaj D, Vivaldi C, Molinari A, Montrone S, Pellerino A, Franchino F, Baldaccini D, Lombardi G, Lolli I, Catania F, Bazzoli E, Morganti R, Fabi A, Zagonel V, Bocci G, Fabrini MG, Rudà R, Soffietti R, Paiar F.

Am J Clin Oncol. 2018 Dec;41(12):1272-1275. doi: 10.1097/COC.0000000000000464.

PMID:
29782366
19.

New insights in the in vitro characterisation and molecular modelling of the P-glycoprotein inhibitory promiscuity.

Bocci G, Moreau A, Vayer P, Denizot C, Fardel O, Parmentier Y.

Eur J Pharm Sci. 2018 Aug 30;121:85-94. doi: 10.1016/j.ejps.2018.04.039. Epub 2018 Apr 28.

PMID:
29709579
20.

Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors.

Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G, Bocci G.

Biochem Pharmacol. 2018 Jun;152:327-337. doi: 10.1016/j.bcp.2018.04.011. Epub 2018 Apr 13.

PMID:
29660315
21.

Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.

Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.

Oncol Rep. 2018 May;39(5):2306-2314. doi: 10.3892/or.2018.6305. Epub 2018 Mar 8.

PMID:
29517106
22.

Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.

Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.

Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8.

PMID:
29517103
23.

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

Di Desidero T, Orlandi P, Fioravanti A, Cremolini C, Loupakis F, Marmorino F, Antoniotti C, Masi G, Lonardi S, Bergamo F, Zagonel V, Falcone A, Bocci G.

Invest New Drugs. 2018 Aug;36(4):709-714. doi: 10.1007/s10637-018-0579-8. Epub 2018 Feb 27.

PMID:
29488048
24.

Malaria chemoprophylaxis' compliance in travelers.

Bocci G, Troiano G, Golinelli D, Verzuri A, Rossi S, Nante N.

Ann Ig. 2018 Jan-Feb;30(1):71-72. doi: 10.7416/ai.2018.2198. Review. No abstract available.

25.

Midwives in England and in Italy: two realities compared.

Dell'Omodarme C, Bocci G, Troiano G, Rossi S, Kundisova L, Nante N, Alaimo L.

Ann Ig. 2018 Jan-Feb;30(1):14-20. doi: 10.7416/ai.2018.2191.

26.

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Cox MC, Musuraca G, Battistini R, Casaroli I, Zoli V, Anticoli-Borza P, Arcari A, Naso V, di Landro F, Fabbri F, Tafuri A, Bocci G, Merli F.

Br J Haematol. 2018 Dec;183(5):819-822. doi: 10.1111/bjh.15039. Epub 2017 Nov 28. No abstract available.

PMID:
29193017
27.

Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy.

Pasqualetti F, Gonnelli A, Cantarella M, Delishaj D, Molinari A, Ortenzi V, Carbone F, Montrone S, Ursino S, Franceschi S, Morganti R, Orlandi P, Di Desidero T, Mazzanti CM, Zavaglia K, Naccarato AG, Bocci G, Paiar F.

Invest New Drugs. 2018 Apr;36(2):340-345. doi: 10.1007/s10637-017-0516-2. Epub 2017 Sep 30.

PMID:
28965273
28.

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Alì G, Fontanini G, Basolo F, Francia G, Bocci G.

Cancer Lett. 2017 Dec 28;411:35-43. doi: 10.1016/j.canlet.2017.09.032. Epub 2017 Sep 28.

PMID:
28964784
29.

Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.

Vaglini F, Pardini C, Di Desidero T, Orlandi P, Pasqualetti F, Ottani A, Pacini S, Giuliani D, Guarini S, Bocci G.

Mol Neurobiol. 2018 Jun;55(6):4984-4997. doi: 10.1007/s12035-017-0702-4. Epub 2017 Aug 8.

PMID:
28791594
30.

The key role of clinical and community health nurses in pharmacovigilance.

Bigi C, Bocci G.

Eur J Clin Pharmacol. 2017 Nov;73(11):1379-1387. doi: 10.1007/s00228-017-2309-0. Epub 2017 Aug 2. Review.

PMID:
28770283
31.

ADME-Space: a new tool for medicinal chemists to explore ADME properties.

Bocci G, Carosati E, Vayer P, Arrault A, Lozano S, Cruciani G.

Sci Rep. 2017 Jul 25;7(1):6359. doi: 10.1038/s41598-017-06692-0.

32.

Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists.

Marinozzi M, Castro Navas FF, Maggioni D, Carosati E, Bocci G, Carloncelli M, Giorgi G, Cruciani G, Fontana R, Russo V.

J Med Chem. 2017 Aug 10;60(15):6548-6562. doi: 10.1021/acs.jmedchem.7b00091. Epub 2017 Jul 25.

PMID:
28741954
33.

Scholars and scientists in the history of the lymphatic system.

Natale G, Bocci G, Ribatti D.

J Anat. 2017 Sep;231(3):417-429. doi: 10.1111/joa.12644. Epub 2017 Jun 14. Review.

34.

Factors that could influence women's participation in colorectal cancer screening: an Italian study.

Bocci G, Troiano G, Messina G, Nante N, Civitelli S.

Ann Ig. 2017 Mar-Apr;29(2):151-160. doi: 10.7416/ai.2017.2142.

35.
36.

Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.

Pasqualetti F, Orlandi P, Simeon V, Cantarella M, Giuliani D, Di Desidero T, Gonnelli A, Delishaj D, Lombardi G, Sechi A, Sanson M, Zagonel V, Paiar F, Danesi R, Guarini S, Bocci G.

Mol Neurobiol. 2018 Feb;55(2):1396-1404. doi: 10.1007/s12035-017-0414-9. Epub 2017 Feb 1.

PMID:
28150230
37.

Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo.

Di Paolo A, Orlandi P, Di Desidero T, Danesi R, Bocci G.

Oncol Res. 2017 Aug 7;25(7):1129-1140. doi: 10.3727/096504017X14841698396900. Epub 2017 Jan 20.

PMID:
28109077
38.

Health status of homeless persons: a pilot study in the Padua municipal dorm.

Levorato S, Bocci G, Troiano G, Messina G, Nante N.

Ann Ig. 2017 Jan-Feb;29(1):54-62. doi: 10.7416/ai.2017.2132.

39.

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.

Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G.

Br J Cancer. 2017 Jan;116(3):324-334. doi: 10.1038/bjc.2016.429. Epub 2017 Jan 5.

40.

Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.

Coltelli L, Fontana A, Lucchesi S, Ginocchi L, Bocci G, Filidei M, Scalese M, Arrighi G, Finale C, Marcucci L, Goletti O, Salvadori B, Ferrarini I, Bona E, Falcone A, Allegrini G.

Breast. 2017 Feb;31:186-191. doi: 10.1016/j.breast.2016.11.006. Epub 2016 Nov 23.

PMID:
27886643
41.

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Bocci G, Kerbel RS.

Nat Rev Clin Oncol. 2016 Nov;13(11):659-673. doi: 10.1038/nrclinonc.2016.64. Epub 2016 May 17. Review.

PMID:
27184418
42.

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G.

Invest New Drugs. 2016 Dec;34(6):760-770. Epub 2016 Aug 24.

PMID:
27557783
43.

Looking for the Word "Angiogenesis" in the History of Health Sciences: From Ancient Times to the First Decades of the Twentieth Century.

Natale G, Bocci G, Lenzi P.

World J Surg. 2017 Jun;41(6):1625-1634. doi: 10.1007/s00268-016-3680-1.

PMID:
27491322
44.

1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.

Coviello V, Marchi B, Sartini S, Quattrini L, Marini AM, Simorini F, Taliani S, Salerno S, Orlandi P, Fioravanti A, Desidero TD, Vullo D, Da Settimo F, Supuran CT, Bocci G, La Motta C.

J Med Chem. 2016 Jul 14;59(13):6547-52. doi: 10.1021/acs.jmedchem.6b00616. Epub 2016 Jun 27.

PMID:
27305384
45.

Metronomic chemotherapy for triple negative breast cancer?

Di Desidero T, Kerbel RS, Bocci G.

Aging (Albany NY). 2016 Apr;8(4):573-4. doi: 10.18632/aging.100947. No abstract available.

46.

Cyto- and enzyme toxicities of ionic liquids modelled on the basis of VolSurf+ descriptors and their principal properties.

Paternò A, Bocci G, Cruciani G, Fortuna CG, Goracci L, Sciré S, Musumarra G.

SAR QSAR Environ Res. 2016 Mar;27(3):221-244. doi: 10.1080/1062936X.2016.1156571.

PMID:
30950653
47.

John Hunter and the origin of the term "angiogenesis".

Lenzi P, Bocci G, Natale G.

Angiogenesis. 2016 Apr;19(2):255-6. doi: 10.1007/s10456-016-9496-7. Epub 2016 Feb 3. No abstract available.

PMID:
26842740
48.

Modelling the aquatic toxicity of ionic liquids by means of VolSurf in silico descriptors.

Paternò A, Bocci G, Goracci L, Musumarra G, Scirè S.

SAR QSAR Environ Res. 2016;27(1):1-15. doi: 10.1080/1062936X.2015.1120778. Epub 2016 Jan 4.

PMID:
26727707
49.

IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.

Lazzeri S, Orlandi P, Piaggi P, Sartini MS, Casini G, Guidi G, Figus M, Fioravanti A, Di Desidero T, Ripandelli G, Parravano M, Varano M, Nardi M, Bocci G.

Pharmacogenomics. 2016;17(1):35-9. doi: 10.2217/pgs.15.153. Epub 2015 Dec 14.

PMID:
26653034
50.

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.

Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS.

Oncotarget. 2015 Dec 15;6(40):42396-410. doi: 10.18632/oncotarget.6377.

Supplemental Content

Support Center